Patents by Inventor Michael G. Strainic

Michael G. Strainic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES
    Publication number: 20220185872
    Abstract: A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.
    Type: Application
    Filed: September 28, 2021
    Publication date: June 16, 2022
    Inventors: M. Edward Medof, Michael G. Strainic, Elliot Pohlmann, Ming-Shih Hwang
  • Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
    Patent number: 11130801
    Abstract: A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: September 28, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: M. Edward Medof, Michael G. Strainic, Elliot Pohlmann, Ming-Shih Hwang
  • COMPOSITIONS AND METHODS OF TREATING A T CELL MEDIATED DISORDER
    Publication number: 20210275585
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Application
    Filed: March 2, 2021
    Publication date: September 9, 2021
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • Compositions and methods of treating a T cell mediated disorder
    Patent number: 10933093
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: March 2, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • COMPOSITIONS AND METHODS FOR MODULATING TOLL LIKE RECEPTOR SIGNAL
    Publication number: 20180256646
    Abstract: A method of method of inhibiting Toll like receptor (TLR) signaling in dendritic cells (DCs) of a subject in need thereof includes administering at least one complement antagonist to the DCs at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the DCs induced by TLR signaling.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 13, 2018
    Inventors: M. Edward Medof, Jinbo Liu, Michael G. Strainic
  • COMPOSITIONS AND METHODS OF TREATING A T CELL MEDIATED DISORDER
    Publication number: 20180228843
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • Compositions and methods of treating T cell mediated disorder
    Patent number: 9937206
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: April 10, 2018
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • METHOD OF TREATING T CELL MEDIATED DISORDERS
    Publication number: 20170027861
    Abstract: A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation.
    Type: Application
    Filed: August 2, 2016
    Publication date: February 2, 2017
    Inventors: M. Edward Medof, Michael G. Strainic, Kristina V. Thomas, Jodi Arth, Fengqi An, Juang Huang
  • Compositions and methods of treating T cell mediated disorder
    Patent number: 9290736
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: March 22, 2016
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • METHOD OF TREATING CANCER
    Publication number: 20150299300
    Abstract: A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.
    Type: Application
    Filed: January 26, 2015
    Publication date: October 22, 2015
    Inventors: M. Edward Medof, Michael G. Strainic, Young A. Choi
  • Method of treating cancer
    Patent number: 8940299
    Abstract: A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: January 27, 2015
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Michael G. Strainic, Young A Choi
  • COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION
    Publication number: 20120315279
    Abstract: A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.
    Type: Application
    Filed: January 13, 2012
    Publication date: December 13, 2012
    Inventors: M. Edward Medof, Michael G. Strainic, Elliott Pohlman, Ming-Shih Hwang
  • COMPOSITIONS AND METHODS OF TREATING T CELL MEDIATED DISORDER
    Publication number: 20120219566
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Application
    Filed: November 4, 2010
    Publication date: August 30, 2012
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • METHOD OF TREATING T CELL MEDIATED DISORDERS
    Publication number: 20110182910
    Abstract: A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation.
    Type: Application
    Filed: March 6, 2009
    Publication date: July 28, 2011
    Inventors: M. Edward Medof, Michael G. Strainic, Kristina V. Thomas, Jodi Arth, Fenqgi An, Juang Huang
  • METHOD OF TREATING CANCER
    Publication number: 20110135656
    Abstract: A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell.
    Type: Application
    Filed: March 2, 2009
    Publication date: June 9, 2011
    Inventors: M. Edward Medof, Michael G. Strainic, Young A Choi